Early management of COPD: Where are we now and where do we go from here? a delphi consensus project by Di Marco, F. et al.
© 2019 Di Marco et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2019:14 353–360
International Journal of COPD
This article was published in the following Dove Press journal: 
International Journal of COPD
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
353
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.s176662
early management of COPD: where are we now 
and where do we go from here? a Delphi 
consensus project
Fabiano Di Marco,1 Piero Balbo,2 
Francesco de Blasio,3 Vittorio 
Cardaci,4 nunzio Crimi,5 
giuseppe girbino,6 girolamo 
Pelaia,7 Pietro Pirina,8 Pietro 
roversi,9 Pierachille santus,10,11 
nicola scichilone,12 alessandro 
Vatrella,13 Patrizio Pasqualetti,14 
Mauro Carone15
1Department of health sciences, University 
of Milan, respiratory Unit, Papa giovanni 
XXIII hospital, Bergamo, Italy; 2sC Malattie 
dell’apparato respiratorio, aOU Maggiore della 
Carità, novara, Italy; 3respiratory Medicine and 
Pulmonary rehabilitation section, Clinic Center 
s.p.a. Private hospital, Department of Medicine 
and health sciences “V Tiberio”, University of 
Molise, Campobasso, Italy; 4Unit of Pulmonary 
rehabilitation, IrCCs “san raffaele Pisana”, 
rome, Italy; 5Unità Operativa Complessa di 
Pneumologia e allergologia, Policlinico rodolico 
Vittorio emanuele, Università di Catania, Catania, 
Italy; 6Dipartimento di scienze Biomediche, 
Odontoiatriche e delle Immagini Morfologiche e 
Funzionali (BIOMOrF), Università degli studi di 
Messina, Messina, Italy; 7Department of Medical and 
surgical sciences, Unit of respiratory Diseases, 
University Magna graecia of Catanzaro, Catanzaro, 
Italy; 8respiratory Unit, aOU sassari, sassari, Italy; 
9azienda Ospedaliera Universitaria, Policlinico di 
Modena, Modena, Italy; 10Department of Biomedical 
and Clinical sciences, University of Milan, Milan, 
Italy; 11Division of respiratory Diseases “l. sacco” 
hospital, assT Fatebenefratelli sacco, Milan, Italy; 
12Dipartimento Biomedico di Medicina Interna 
e specialistica (DIBIMIs), University of Palermo, 
Palermo, Italy; 13Department of Medicine, surgery 
and Dentistry “scuola Medica salernitana”, 
University of salerno, salerno, Italy; 14Fondazione 
Fatebenefratelli per la ricerca e la Formazione 
sanitaria e sociale, rome, Italy; 15Istituti Clinici 
scientifici Maugeri, IrCCs di Cassano delle Murge, 
Cassano delle Murge (Ba), Italy
Purpose: There is a lack of consensus on the most appropriate early diagnostic strategy, criteria 
for early access to treatment and follow-up approach for patients with COPD.
Materials and methods: A Delphi consensus project investigated the early management of 
COPD. We formulated two questionnaires for completion by pneumologists in Italy.
Results: A total of 207 specialists completed questionnaire 1 and 184 of them questionnaire 2, 
between November 2016 and October 2017. Early diagnosis of COPD was considered uncommon 
for 93.2% of the expert panel. Regardless of the definition of “early diagnosis” – a diagnosis 
made before the clinical manifestation of the disease for most responders (60.4%) – experts were 
confident of the positive effects of early disease management, which they consider is effective 
in modifying the natural history of the disease. Lack of awareness of the disease was considered 
the first limiting factor to early COPD management for 78% of respondents. The most effec-
tive steps to reduce functional decline were considered to be smoking cessation, followed by 
long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA), LAMA, LABA, 
and finally inhaled corticosteroid/LABA (P,0.01 for each paired comparison). Specialists 
considered it “inappropriate” for general practitioners to perform both the early diagnosis and 
therapy of COPD without the involvement of a specialist.
Conclusion: Early management of COPD is uncommon, and although data on the effects of 
early disease management on long-term outcomes are limited, Italian experts are confident of 
the clinical efficacy of this approach.
Keywords: Italy, bronchodilator therapy, respiratory symptoms, dyspnea
Introduction
COPD is defined as a “preventable and treatable disease, which is characterised by 
persistent airflow limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious particles or gases.” 
It is a major cause of morbidity and mortality worldwide.1 Total deaths from COPD are 
projected to increase by .30% in the next 10 years, and according to The Global Burden 
of Disease Study, in 2020 COPD will be the third leading cause of death worldwide.2 
Previously, COPD was more common in men, but because of increased tobacco use 
among women in high-income countries and the higher risk of exposure to indoor air 
pollution in low-income countries, the disease now affects men and women almost 
equally. In the International Burden of Obstructive Lung Diseases (BOLD) survey, the 
prevalence of spirometrically confirmed COPD in adults was estimated to be 10%.3
In the majority of patients, COPD is a progressive condition, with deteriorating lung 
function over time in addition to the natural decline in pulmonary function that occurs 
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with increasing age. This debilitating and chronic disease 
carries a significant economic burden on both individuals 
and society, with direct healthcare costs due primarily to 
exacerbation-related hospitalizations and indirect costs due 
to loss of productivity.1,4 The prognosis for COPD patients 
depends on the severity of disease, those with severe disease 
are more prone to severe exacerbations, hospitalizations, 
respiratory failure, and death. Patients with milder disease 
are at less risk of the above but have an increased risk of 
disease progression.5 Moreover, patients with mild COPD 
have a reduced quality of life/exercise tolerance and increased 
healthcare resource utilization.
Early intervention in COPD, with smoking cessation, 
pharmacological therapy, and non-pharmacological treat-
ment options such as rehabilitation, can reduce decline in lung 
function and the risk of exacerbations and improve quality 
of life, as demonstrated by a recent paper which showed the 
efficacy of the long-acting muscarinic antagonist (LAMA), 
tiotropium, on FEV
1
 decline in patients with early stage 
disease.5,6 Unfortunately, despite the rising prevalence and 
substantial socioeconomic impact of COPD, misdiagnosis 
and underdiagnosis continue to be a central problem in the 
management of this disease. Generally, many people with 
COPD, especially those with mild and moderate disease, 
remain underrecognized, underdiagnosed, and undertreated, 
even though it is now considered to be treatable.7,8 Undi-
agnosed early stage COPD, particularly in symptomatic 
patients, is therefore likely to progress to more severe stages 
of the disease.
Consensus group methods such the Delphi method have 
been used successfully in medicine to synthesize expert 
opinion when GOLD standard evidence is not available.9,10 
We conducted a Delphi consensus project to investigate the 
opinions on the early management of COPD patients – needs, 
approach to diagnosis and treatment, as well as suggestions 
on how to improve the early management of COPD.
Materials and methods
The Delphi technique is a validated process to develop 
consensus and make group-based decisions.11,12 Our study 
was conducted in four phases: 1) development of the survey 
questionnaire by the scientific committee; 2) selection of 
the expert panel; 3) completion of the online survey in two 
rounds; and 4) analysis of results and discussion of conclu-
sions at an onsite meeting with the scientific committee.
Delphi process
The study was undertaken between November 2016 and 
September 2017. An advisory board (comprised 13 specialists 
from Italian universities and public hospitals) reviewed the 
medical literature on the early management of COPD and 
developed a questionnaire (Q1) (Supplementary material) 
including a set of seven demographic and organizational items 
and a second set of 27 scientific items focusing on epidemio-
logical, diagnostic, and therapeutic topics. Questionnaire Q1 
was administered, according to the Delphi method, to an expert 
panel comprising pulmonologists from the Italian healthcare 
system recommended by the scientific committee accord-
ing to the geographical area. For some items participants 
expressed their opinion on a Likert scale between 0 and 5, 
while for other items they ordered a set of options according 
to relevance matching their clinical experience. They also 
answered open questions. After the ratings from the first round 
were statistically analyzed, a second questionnaire (Q2) was 
drawn up and sent to the same professionals who responded 
to Q1 (Supplementary material). Q2, which included 
22 items, was intended to better focus on some aspects and 
to solve certain ambiguities that emerged from Q1.
Research ethics, confidentially, informed consent, 
and data protection
Our Delphi study conformed to general ethical requirements 
aiming to assure “rigor, respect, and responsibility” in the 
conduct of research projects. The study as such was exempt 
from the need to obtain formal ethical board approval. 
Rights involved in the research study were explained at the 
outset, and by returning the questionnaires, the participants 
gave their consent to take part in the study. These measures 
support the ethical principles of respect and the right of 
self-determination and of obtaining an informed consent. No 
personal information was collected, and survey responses 
were collated anonymously. All responses received in the 
study were kept confidential, and identities of individual 
participants were not divulged. Survey responses were 
collected online using a secure Internet server and retained 
for the duration of the study.
statistical analyses
To assess the agreement among the experts, the Delphi 
method uses a scale from 1 (maximal disagreement) to 9 
(maximal agreement), with 5 corresponding to a neutral 
opinion about a given item. Thus, scores given by experts 
are statistically elaborated to obtain an appropriate “index of 
consensus.” Inter-percentile Range Adjusted for Symmetry 
(IPRAS) scores were employed as indicators of the extent 
of agreement for each item. Using the inter-percentile range/
IPRAS computation, each statement can be classified with the 
appropriateness of a given diagnostic/therapeutic strategy in 
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the following categories: appropriate (panel median of 7–9, 
without disagreement), uncertain (panel median of 4–6 or 
any median with disagreement), inappropriate (panel median 
of 1–3, without disagreement). When ranked in order of 
importance – 1 was an indicator of the most inappropriate/
irrelevant and 5 the most appropriate/relevant. Total scores 
indicate experts’ level of preference with only those reaching 
50% (of maximum) considered and reported. A two-sided 
significance level α of 0.05 was defined (mean ± SD). As a 
general rule, non-parametric tests were applied to assess the 
differences between groups (Kruskal–Wallis and Mann–Whit-
ney) and between items (Friedman and Wilcoxon). Bonferroni 
adjustment was carried out for multiple comparisons.
Results
The scientific committee recommended that Q1 was sent 
to 515 pneumologists and allergists working in the Italian 
healthcare system. The expert panel was representative of 
the geographic distribution of the hospital and/or university 
respiratory units in Italy. Feedback was received from 
207 clinicians (40% of those initially approached) with a 
geographical distribution as follows: North (39.1%), Central 
(29.9%), and South (30.9%). Q2 was dispatched to all those 
who had previously replied to Q1 (207 experts), and replies 
were received from 184 (90%). Most clinicians participating 
in the Delphi study were specialist pneumologists (92.8%).
The average age of all the 207 respondents of Q1 was 
53.2±9.2 years. Fifty-two were women (25%) and 155 men 
(75%). In line with the demographics of medical doctors in 
Italy, there are more male doctors than female doctors, and 
female doctors tend to be younger than male doctors (47.4±9.7 
and 55.1±8.1 years, respectively). About 21% of the respon-
dents work in respiratory centers with beds reserved 
for rehabilitation, with spirometers available in 99% of 
cases. Diffusing capacity of the lungs for carbon mon-
oxide measurement was available in 90%, body plethys-
mograph in 87%, dosimeter for methacholine in 80%, 
and cardiopulmonary exercise test in 63%. Waiting 
times for a spirometry was estimated to be ,30 days for 
56% of respondents, between 30 and 60 days for 30%, 
and .60 days for the remaining 14%. On average, 62% of 
patients were referred to specialists by their general practi-
tioners (GPs) and the remaining 38% referred themselves.
Meaning and importance of “early 
diagnosis” of COPD
An “early diagnosis” of COPD was considered to be a 
diagnosis made before clinical manifestation of the disease by 
the majority of responders (60.4%) (ie, primary prevention); 
a diagnosis when COPD is mild (secondary prevention) for 
33.8% of responders. Only 5.8% of the responders believe 
that early diagnosis is an approach aimed at reducing 
the complications of the disease (ie, tertiary prevention). 
As a general rule, responders were confident of the positive 
effect of early management of the disease, with a high level 
of consensus on the question “does an early diagnosis affect 
the natural history of the disease?” (median of 8.0/9.0 with 
an interquartile range [IQR] of 7–9, Figure 1). Furthermore, 
95.7% of responders were convinced that early management 
of the disease can affect therapeutic success. Moreover, over 
90% of the responders treat patients with mild obstruction 
(ie, FEV
1
 .80%) in all cases (20%) or in the presence of 
symptoms (70%).
Early diagnosis of COPD: fact or fiction?
According to those who responded, early diagnosis of 
COPD is uncommon with only 6.8% of the expert panel 
stating that it occurs in real-life clinical practice. Accord-
ing to the expert panel, factors limiting early diagnosis and 
treatment of COPD are (in order to importance): lack of 
awareness about the disease (78% of respondents), “lack of 
interest” by GPs (41%), not a priority disease for GPs even 
if they understand its importance (48%), and difficulties in 
performing spirometry (57%) (Figure 2). In total, 12% of 
the responders replied that on average, new patients report 
that they have symptoms for ,1 year. Importantly, experts 
replied that only 15% of patients received a diagnosis 
when their disease was still mild according to spirometry 
(GOLD 1) and 15.8% were diagnosed according to symptoms/ 
exacerbations (GOLD 1).
early diagnosis/screening: who should be 
evaluated?
In reply to the question which categories of smokers should 
have an early diagnosis, the Expert Panel gave the following 
importance scores (possible range: min =1, max =5): heavy 
smokers, 4.2; smokers with comorbidities, 4.0; and young 
smokers, 3.8. Each pairwise Wilcoxon paired comparison 
(following a significant overall Friedman’s test, P,0.001) 
resulted statistically significant (consistently, P,0.020).
Treating patients with mild COPD: the 
pharmacological approach
According to the expert panel, the role of patient preference 
in the choice of therapy is not affected by early diagnosis 
of the disease (4.0/5.0 in both cases, P=0.136). The level of 
confidence in the different approaches used to reduce the 
functional decline in mild COPD were stopping smoking 
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Figure 1 level of consensus on the early management of COPD.
Abbreviations: gP, general practitioner; IPras, Inter-percentile range adjusted for symmetry.
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Figure 2 relevance of factors limiting early diagnosis of COPD according to expert panel.
Note: First, second, third, and fourth refer to the rank order of the answers.
Abbreviation: gP, general practitioner.
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(highest score), followed by a LAMA plus long-acting beta-
agonist (LABA), a LAMA, a LABA, and finally inhaled 
corticosteroid (ICS) plus LABA (P,0.01) for each paired 
comparison (Figure 3). In patients with MRC $2 dyspnea and 
a FEV
1
 between 50% and 80% (moderate obstruction), the 
level of consensus in different treatments in both younger and 
older patients is reported in Figure 4 (each paired comparison 
is significantly different, P,0.001). In terms of appropriate-
ness, the order was 1) LABA/LAMA; 2) single bronchodila-
tor; 3) ICS/LABA; 4) no treatment in both cases with age 
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Figure 3 Level of confidence in different approaches used in the early management of COPD to reduce the functional decline.
Note: Each pairwise comparison was significant (P,0.001).
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting beta-agonist; laMa, long-acting muscarinic antagonist.
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Figure 4 level of consensus on different treatments in patients younger and older with moderate obstruction (mean ± 95% CI).
Abbreviations: ICs, inhaled corticosteroid; laBa, long-acting beta-agonist; laMa, long-acting muscarinic antagonist.
having a significant effect (P,0.001). The appropriateness 
of starting with a single bronchodilator (although lower than 
that of starting with LABA/LAMA) had a higher level of 
consensus when applied in young patients, whereas LABA/
LAMA was assigned a higher level of appropriateness for 
older patients (Figure 4).
Improving early management of COPD 
patients
Over 50% said that they would be available to promote/be 
involved in a specific campaign aimed at increasing the level of 
early management in COPD and over 30% would be available to 
take part in such an initiative organized by a scientific society.
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Subjects to be screened should be selected by GPs 
(approach considered “appropriate”: median =8, IQR =7–9), 
while experts are less certain about the role of GPs in 
spirometry (median =6, IQR =4–8). The involvement of 
a specialist in the field was considered crucial and respon-
dents considered it “inappropriate” for GPs to perform 
both diagnosis and therapy of these patients (median =2, 
IQR =3–4) without the involvement of a specialist (Figure 1). 
The tools considered “appropriate” to select subjects to be 
evaluated for early diagnosis are questionnaires carried 
out during clinical evaluation (median =7, IQR =6–8) and 
analysis of the GP database to identify patients treated with 
bronchodilators (median =7, IQR =5–8). Experts were less 
sure about a selection based on the use of systemic steroids 
and/or antibiotics (median =6, IQR =5–8). Experts consid-
ered that once early diagnosis was made, follow-up should 
be carried out by specialists rather than GPs (4.4 vs 2.8 in a 
1–5 scale, P,0.001, Figure 1).
Discussion
Our Delphi-based study focused on open issues on the 
optimal strategy for the therapeutic management of patients 
with early stage COPD. A two-round Delphi consensus 
explored the opinions of a large number of pneumologists in 
Italy on the early diagnosis and treatment of COPD. This is 
one of the few studies to involve such a large cohort of 
pneumologists (515 experts received the first questionnaire, 
with 207 replying). Other recently reported study involved up 
to a maximum of 200 experts in respiratory medcine.13–18
Results of our study show that the majority of experts 
agreed on most of the proposed items and replies were in-line 
with the GOLD 2017 recommendations.1 COPD is a progres-
sive condition, and early diagnosis may allow a change in the 
natural history of COPD with significant savings both in terms 
of costs to health care systems as well as to patients.19
Smoking cessation is vital to modify the natural history 
of COPD.20,21 Early pharmacological therapy has also been 
recognized as an important factor in slowing down the 
functional decline, reducing the exacerbations/long-term 
consequences, and improving the quality of life.22–26 Although 
it is generally accepted that pharmacological therapy should 
be considered a possible early intervention in COPD, 
the optimal maintenance therapy – single bronchodilator 
(short- or long-acting LAMA or LABA) vs LABA-LAMA 
vs ICS-LABA – is still being debated.27
Our panel of experts addressed these issues and reached a 
series of outcomes. First, they agreed that an early diagnosis 
must include primary and secondary prevention (.95% of 
responders). They were confident that early management 
of COPD could affect its natural history and over 90% of 
panelists confirmed that starting long-acting bronchodilators 
in mildly obstructed both symptomatic and asymptomatic 
patients was appropriate. American College of Physicians, 
American College of Chest Physicians, American Thoracic 
Society, and European Respiratory Society guidelines state 
that available evidence is not sufficient to recommend the 
use of bronchodilators in asymptomatic individuals.28 The 
results of our Delphi consensus are in general agreement 
with international guidelines as the majority of specialists 
stated they would treat “mild” disease only in the presence 
of symptoms (70%) and 20% of them sustained that they 
would treat asymptomatic patients. Nevertheless, there is 
some evidence that mild/moderate obstruction of airflow can 
present without actual symptoms and a number of studies 
report a cohort of patients as COPD patients who have so-
called silent obstruction in the absence of symptoms (chronic 
cough, phlegm, and/or dyspnea) but with airflow limitation 
on spirometric examinations.29–32 This is not a completely 
unexpected finding given that the severity of symptoms 
and airway obstruction are weakly correlated.33 It therefore 
follows that early intervention may delay or even avoid not 
just the manifestation of symptoms but also other clinical 
indicators, such as acute exacerbations, with their attendant 
long-term consequences. While there is some evidence to 
support this hypothesis, it needs to be evaluated in prospec-
tive clinical trials, as the impact of pharmacological therapy 
in comparison with smoking cessation is not yet known.34
Our results are similar to those reported by another group 
of Italian specialists in COPD.35 In our study, experts did 
not reach a consensus on the effectiveness of increasing the 
dosage of bronchodilators to better control COPD, but a 
substantial number considered this to be a fitting approach. 
In fact, in everyday life, a patient on monotherapy expe-
riencing breathing difficulties will frequently increase the 
dosage of his/her bronchodilator in the hope of improving 
symptoms.35,36 Results of our study confirmed previous 
investigations and the majority of experts were in agreement 
that patients not fully controlled with a single bronchodila-
tor should receive another bronchodilator preferably with 
a different mechanism of action.35 It is now well accepted 
that the combination of a LABA and LAMA is the most 
appropriate treatment for early COPD, especially in older 
patients (P,0.001) (Figure 4). Using multiple drugs in 
combination has a number of important advantages includ-
ing decreasing the possibility of adverse effects, simplifying 
treatment regimens, and increasing adherence to therapy.37
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International guidelines (GOLD 2017, 2018) endorse the 
use of LABAs in combination with antimuscarinics if there is 
no adequate improvement in symptoms with monotherapy.1 
Dual therapy such as fixed combinations of LABA and 
LAMA has been shown to play an important role in obtaining 
maximum bronchodilator effects. Results of clinical trials 
suggest that fixed dose combination bronchodilator therapy 
provides significantly greater improvements in lung function 
compared with monotherapy although the precise mechanism 
has yet to be fully elucidated.35,38,39 It should also be noted 
that combination therapy is well tolerated in patients with 
moderate-to-severe COPD.1
Unfortunately, early diagnosis in real-life clinical practice 
is as yet uncommon not least because patients are referred to 
specialists when they have moderate to advanced disease. 
According to our group of experts, the main reason for this 
seems to a lack of awareness about the disease (77% of 
responders). It is therefore vital to find strategies to increase 
patient and physician awareness about COPD, especially in 
heavy smokers (score 4.2/5 in our expert panel) or when more 
comorbidities are present (score 4/5). Moreover, even when an 
early diagnosis is made, non-adherence to medication regimens 
is a significant problem in the management of COPD.40 It is 
therefore vital, according to the panel, when faced with a situa-
tion where symptoms are not controlled, to first establish if the 
patient is actually taking the medication as prescribed before 
deciding to change to a different medication or to increase 
the dosage of an existing medication (median 7.5, IQR =7–8).
Conclusion
Early management of COPD is not common, and although 
there are limited data on the effects of early disease manage-
ment on long-term outcomes, Italian experts are confident 
of the clinical efficacy of this approach. Smoking cessation 
should be the first step followed by pharmacological thera-
pies. The expert panel was in agreement on the important 
role of fixed dosage LABA/LAMA on the natural history 
of the disease and in preventing/ameliorating functional 
decline. Finally, the expert panel considered that while GPs 
are crucial for early diagnosis, the role of specialist is vital 
in the early management of COPD patients.
The advantage of consensus panels in general and our 
Delphi study in particular is that they allow expert opinion 
on a wide variety of topics to be captured – in our case 
on the management of COPD. While results support the 
everyday decision-making process in the management of 
early COPD, they only mirror the Italian situation, and as 
such, we consider that a multinational survey is necessary 
to support the consensus scenario and to further investigate 
some of the issues not yet completely addressed by the current 
international guidelines.
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